Drug Discovery Toxicology Specialty Section-Society of Toxicology (DDTSS-SOT)

Dear DDTSS members, We have 4 open positions for this coming year’s election! Vice President-Elect (presidential chain: 4-year commitment) Councilor (2-year commitment) Postdoctoral Representative (2-year commitment) Graduate Student Representative (2-year commitment) If you’re interested in becoming a part of the DDTSS leadership team, please email Sarah Carratt, PhD, DABT <Sarah.Carratt@pfizer.com> your name and the position you would like to nominate yourself for no later than Wednesday, November 13th. A biosketch is not needed at this first step. Please keep in mind that all candidates for the Presidential Chain must be Full, Associate, Retired or Emeritus Members of SOT.   Serving as an officer in DDTSS is an extremely rewarding experience, so please consider applying! We’re looking forward to your nominations.

🎯 Don’t Miss the Mark! How Secondary Pharmacology Can Affect Pharmaceutical Drug Development Thursday, December 5, 2024 11:00 AM to 12:30 PM (US EST) The Society of Toxicology (SOT) Drug Discovery Toxicology and Computational Toxicology Specialty Sections, together with the British Toxicology Society Discovery Toxicology Specialty Section, are excited to jointly host a webinar on state-of-the-art in secondary pharmacology and its impact on the safety of new medicines. Secondary pharmacology screening of investigational small-molecule drugs for potentially adverse off-target activities has become standard practice in pharmaceutical research and development, and regulatory agencies are increasingly requesting data on activity against targets with recognized adverse effect relationships. However, the screening strategies and target panels used by pharmaceutical companies vary substantially. This webinar will feature Dr. Jean-Pierre Valentin (UCB Biopharma) and Friedemann Schmidt (Sanofi), both experienced safety scientists in the pharma industry, who will present on behalf of colleagues from the International Consortium for Innovation and Quality in Pharmaceutical Development Secondary Pharmacology Working Group. This event will be an exciting opportunity to learn about how secondary pharmacology assessment is being positioned today and in the future. Additionally, the discussion will include advances in secondary pharmacology technology and opportunities and challenges in this rapidly developing field. Speaker(s): Jean-Pierre Valentin, Head of Investigative Toxicology, UCB Biopharma SRL Friedemann Schmidt, Head of Digital Toxicology, Sanofi

🎯 Don’t Miss the Mark! How Secondary Pharmacology Can Affect Pharmaceutical Drug Development Thursday, December 5, 2024 11:00 AM to 12:30 PM (US EST) The Society of Toxicology (SOT) Drug Discovery Toxicology and Computational Toxicology Specialty Sections, together with the British Toxicology Society Discovery Toxicology Specialty Section, are excited to jointly host a webinar on state-of-the-art in secondary pharmacology and its impact on the safety of new medicines. Secondary pharmacology screening of investigational small-molecule drugs for potentially adverse off-target activities has become standard practice in pharmaceutical research and development, and regulatory agencies are increasingly requesting data on activity against targets with recognized adverse effect relationships. However, the screening strategies and target panels used by pharmaceutical companies vary substantially. This webinar will feature Dr. Jean-Pierre Valentin (UCB Biopharma) and Friedemann Schmidt (Sanofi), both experienced safety scientists in the pharma industry, who will present on behalf of colleagues from the International Consortium for Innovation and Quality in Pharmaceutical Development Secondary Pharmacology Working Group. This event will be an exciting opportunity to learn about how secondary pharmacology assessment is being positioned today and in the future. Additionally, the discussion will include advances in secondary pharmacology technology and opportunities and challenges in this rapidly developing field. Speaker(s): Jean-Pierre Valentin, Head of Investigative Toxicology, UCB Biopharma SRL Friedemann Schmidt, Head of Digital Toxicology, Sanofi

Dear DDTSS members, We have 4 open positions for this coming year’s election! Vice President-Elect (presidential chain: 4-year commitment) Councilor (2-year commitment) Postdoctoral Representative (2-year commitment) Graduate Student Representative (2-year commitment) If you’re interested in becoming a part of the DDTSS leadership team, please email Sarah Carratt, PhD, DABT <Sarah.Carratt@pfizer.com> your name and the position you would like to nominate yourself for no later than Wednesday, November 13th. A biosketch is not needed at this first step. Please keep in mind that all candidates for the Presidential Chain must be Full, Associate, Retired or Emeritus Members of SOT.   Serving as an officer in DDTSS is an extremely rewarding experience, so please consider applying! We’re looking forward to your nominations.

A free #SOTWebinar on October 18 will cover the different types of toxicology studies conducted to support Investigational New Drug (IND) and New Drug Application (NDA) filings for small molecules.

Don't forget to register for a great webinar this Thursday from the 2023 POY Awardee!

Join the SOT Drug Discovery Toxicology Specialty Section September 19 when the 2023 Drug Discovery Paper of the Year award recipient, Elana Chung, will present her work on QSAR carcinogenicity models using bioassays.

Dear DDTSS Members, The Drug Discovery Toxicology Specialty Section (DDTSS) proudly announces an upcoming webinar to feature the 2023 Paper of the Year. The Paper of the Year Award recognizes scientific achievement in Discovery Toxicology. At the reception, during the SOT 63rd Annual Meeting (2024), DDTSS announced that the recipient for the 2023 Paper of the Year is Elena Chung and her colleagues for their paper “Data-Driven Quantitative Structure-Activity Relationship Modeling for Human Carcinogenicity by Chronic Oral Exposure” published in Environmental Science & Technology (Apr 11 2024; 57(16):6573-88; PMID 37040559). Join us as Elena will present her and her co-authors' work on their QSAR carcinogenicity model using bioassays. Who: Elena Chung, PhD Student in the Pharmaceutical Chemistry Program at Rowan University; Tulane University School of Medicine’s Division of Bioinformatics & Genomics What: 2023 Drug Discovery Paper of the Year When: September 19th, 2024 at 12PM PST / 2PM CT / 3PM EST Publication: https://lnkd.in/g4ki4qte Register: https://lnkd.in/g2c3Ztnt Thank you, DDTSS Leadership

Dear DDTSS Members,   This is a polite reminder to sign up for our co-hosted joint, with the Computational Toxicology Specialty Section, webinar titled “Advancing Toxicology in Drug Discovery using Generative Adversarial Networks” on February 8th, 2024, from 2:00 PM to 3:00 PM EST. This webinar delves into the integration of Generative Adversarial Networks (GANs) models in toxicology, from their foundational principles to applications in drug discovery. Attendees will gain insights into the capabilities and potential of GANs, fostering a better understanding of their role in modern toxicological studies. Please register for this free webinar using the link below. https://lnkd.in/euXFaXmW Thank you, DDTSS Exec Team